● Presence of manic/hypomanic episodes that may alternate with depressive episodes
● overconfidence, grandiosity, talkativeness, extreme disinhibition, irritability, decreased
need for sleep, and highly elevated mood
● Psychotic symptoms such as delusions and hallucinations occur in up to 75% of manic
episodes
● Bipolar I : manic episodes
● Bipolar II : hypomanic episodes
● The presence of at least one hypomanic episode in a life trajectory is considered to be
consistent with the diagnosis of bipolar II disorder
● Cyclothymic disorder is characterized by recurrent depressive and hypomanic states,
lasting for at least 2 years, that do not meet the diagnostic threshold for a major affective
episode
● DSM : symptoms must be present for 1 week for a diagnosis of a manic episode or 2
weeks for diagnosis of depressive episode
● Onset : 20 years
● An earlier onset is often associated with a poorer prognosis, longer treatment delays,
more severe depressive episodes, and higher prevalences of concurrent anxiety and
substance use disorders
● First episode usually depressive - misclassified as major depressive disorder
● In a ⅓ of affected persons not diagnosed until 10 years after onset
Epidemiology and burden
● Lifetime prevalence 2.4%
● 12 month prevalence 1.5%
● Prevalence varies by country
● Bipolar I M=W
● Bipolar II W>M
● Tentative associations between IBS, childhood adversity and bipolar disorder
● Cognitive and psychosocial dysfunction during acute episode
● 6-7% commit suicide
● High rates of comorbid disorders
○ Anxiety
○ Substance use
○ Personality disorder
○ Adhd
● Metabolic syndrome, migraine, obesity, type 2 diabetes more common
● Twice the risk of death (suicide/medical condition)
,Genetic and neurobiological features
● Common variants of genetic risk only account for 25% of heritability
● Gene-environment interaction
● Kindling hypothesis : first episode due to stressor, subsequent episodes can occur
without exposure to stressor
● Poorly characterized epigenetic mechanisms contribute to kindling phenomenon
● Progressive changes in brain structure → reduced cortical thickness in pfc, pathways
subserving neuroplasticity, inflammation, increase in stress
● Deregulation of mitochondrial function
● Aberrations in HPA AXIS → Pathophysiology and progression of bipolar disorder
● Neuroprogression → worsening of cognitive and functional impairments
● Prevalence of type 2 diabetes higher in people with multi episode bipolar
● As bipolar illness progresses, the response to mood stabilizing medications may
decrease
, Management
● Primary care practice improve mental and physical health outcomes
● Medical and psychiatric conditions that mimic affective episodes should be ruled out
during diagnostic assessment
● Selection of initial treatment : patient’s preference, coexisting medical and psychiatric
conditions, previous responses to treatment
● During acute affective episodes the safety of the patient should be ensured
● Evidence based pharmacologic interventions
Treatment of acute episodes
● Acute mania
○ Antipsychotic agents/mood stabilizers
○ If there is no response to a medication after ½ weeks a different medication may
be considered
○ Antipsychotic + mood stabilizer for severe mania
○ In children risperidone > lithium
○ A lot of metabolic adverse depression
○ Haloperidol, paliperidone
○ Electroconvulsive therapy
● Acute depression
○ A low initial dose with gradual upward dose adjustment
○ Combination therapies = antipsychotics and mood stabilizers
○ Rct :ketamine
○ Affective switches - treatment with antidepressants may carry a risk of switches
to hypomania/mania + accelerated cycling between them
○ Second generation antidepressants (SSRIs) may be effective for short term
management of bipolar disorder
○ Risk of mania switches higher in Bipolar I patients → antidepressants avoided
○ Ect effective for patients with treatment resistant and multitherapy resistant
bipolar depression
○ Psychoeducation, cbt, family focused therapy, DBT, MBCT, ITP, social rhythm
therapy
○ children/adolescents : family education + CBT
● Maintenance treatment
○ Combination of pharmacologic, psychological and lifestyle interventions
○ Ideally maintenance treatment started shortly after onset of illness
○ Lithium monotherapy more effective in preventing manic and depressive
episodes
■ Side effects : renal failure, hypothyroidism, polydipsia, tremors, increase
in parathyroid hormone levels
○ Meta Analysis : lithium, antipsychotics may reduce long term morbidity in juvenile
bd
○ Side effects
○ Divalproex - teratogen → not recommended for women of childbearing age
○ Maintenance ect
Les avantages d'acheter des résumés chez Stuvia:
Qualité garantie par les avis des clients
Les clients de Stuvia ont évalués plus de 700 000 résumés. C'est comme ça que vous savez que vous achetez les meilleurs documents.
L’achat facile et rapide
Vous pouvez payer rapidement avec iDeal, carte de crédit ou Stuvia-crédit pour les résumés. Il n'y a pas d'adhésion nécessaire.
Focus sur l’essentiel
Vos camarades écrivent eux-mêmes les notes d’étude, c’est pourquoi les documents sont toujours fiables et à jour. Cela garantit que vous arrivez rapidement au coeur du matériel.
Foire aux questions
Qu'est-ce que j'obtiens en achetant ce document ?
Vous obtenez un PDF, disponible immédiatement après votre achat. Le document acheté est accessible à tout moment, n'importe où et indéfiniment via votre profil.
Garantie de remboursement : comment ça marche ?
Notre garantie de satisfaction garantit que vous trouverez toujours un document d'étude qui vous convient. Vous remplissez un formulaire et notre équipe du service client s'occupe du reste.
Auprès de qui est-ce que j'achète ce résumé ?
Stuvia est une place de marché. Alors, vous n'achetez donc pas ce document chez nous, mais auprès du vendeur stasamilenkovic2002. Stuvia facilite les paiements au vendeur.
Est-ce que j'aurai un abonnement?
Non, vous n'achetez ce résumé que pour 6,49 €. Vous n'êtes lié à rien après votre achat.